Mestastop Solutions, a biotechnology startup based in Bengaluru, has raised Rs 4.5 crore or $500k in a Pre Series A round led by 92 angels & Malpani Ventures. In 2021, the company had secured a seed funding of Rs 2 crore led by IIM Ahmedabad’s CIIE with participation from IKP and angel investors.

Founded by Arnab Roy Chowdhury and Debabani Roy Chowdhury, Mestastop is creating a cancer metastasis focused platform, which uses wet lab biology and predictive analytics to identify and distinguish unique properties of metastasis and leverage them for drug discovery and patient treatment.

The funds will be used to generate proof of concept data with small molecules around the identified first-in-class targets and also help progress drug repurposing efforts to delay metastasis by identifying probable clinical candidates. New animal models and clinical studies will also be supported, along with strategic business development activities.  

The global cost of cancer as a disease burden is poised to be around $25 trillion by 2050. The spending on treating and research for curing cancer across would hit $400 billion by 2030. Of this, global drug discovery market size is poised to hit $150-180 billion around that time.